Literature DB >> 4005132

Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

F Theeuwes, D R Swanson, G Guittard, A Ayer, S Khanna.   

Abstract

The essential features and mode of action of oral osmotic drug delivery systems (Oros) for metoprolol fumarate and oxprenolol succinate are described. Critical aspects in the development of systems for once-daily administration of both drugs are discussed, and methods for evaluating in vitro release characteristics are presented. In vitro testing confirmed that drug delivery corresponded closely to the theoretical release behaviour predicted from the physicochemical and membrane permeability characteristics for both oxprenolol and metoprolol systems. In vitro release rates were also shown to be unaffected by pH, in vitro test procedures, dissolution media and long-term storage at different temperatures.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005132      PMCID: PMC1463768          DOI: 10.1111/j.1365-2125.1985.tb02745.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Elementary osmotic pump.

Authors:  F Theeuwes
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

3.  Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.

Authors:  C P Quaterman; M J Kendall; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

4.  A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.

Authors:  M J West; M J Kendall; M Mitchard; E B Faragher
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

5.  A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.

Authors:  M J Kendall; V A John; C P Quarterman; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

6.  Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.

Authors:  W J Leahey; J D Neill; M P Varma; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

7.  Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment.

Authors:  C Bengtsson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

8.  Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension.

Authors:  J C Petrie; T A Jeffers; O J Robb; A K Scott; J Webster
Journal:  Br Med J       Date:  1980-06-28

9.  Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise.

Authors:  A Bobik; G L Jennings; P I Korner; P Ashley; G Jackman
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

10.  Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.

Authors:  S Freestone; J H Silas; M S Lennard; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

  10 in total
  21 in total

1.  Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy.

Authors:  S S Davis; N Washington; G D Parr; A H Short; V A John; P Lloyd; S M Walker
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

2.  Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.

Authors:  G T McInnes; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion.

Authors:  M A van Baak; F T Verstappen; B Oosterhuis
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Jejunal and ileal absorption of oxprenolol in man: influence of nutrients and digestive secretions on jejunal absorption and systemic availability.

Authors:  J Godbillon; N Vidon; R Palma; A Pfeiffer; C Franchisseur; M Bovet; G Gosset; J J Bernier; J Hirtz
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

Review 5.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

6.  Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form.

Authors:  D B Jack; M J Kendall; S J Laugher; S R Smith
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  Design of a new multiple-unit controlled-release formulation of metoprolol--metoprolol CR.

Authors:  A Sandberg; G Ragnarsson; U E Jonsson; J Sjögren
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers.

Authors:  I R Wilding; S S Davis; J G Hardy; C S Robertson; V A John; M L Powell; M Leal; P Lloyd; S M Walker
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

9.  CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers.

Authors:  A L van Steveninck; M S Pieters; H C Schoemaker; D D Breimer; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

10.  Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing.

Authors:  A Sandberg; B Abrahamsson; A Svenheden; B Olofsson; R Bergstrand
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.